Pharma BD Deal Intelligence
Novartis acquired Gyroscope Therapeutics for $1.5B for gene therapy for retinal diseases.
Novartis to acquire Gyroscope Therapeutics for up to $1.5 billion for gene therapy targeting geographic atrophy.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Novartis acquired Gyroscope Therapeutics for $1.5B for gene therapy for retinal diseases.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / Gyroscope Therapeutics (this deal) | 2021 | $1.5B | 23 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2021 deals · Novartis AG deals · Gene Therapy deals